Skip to main content
. 2023 Jul 6;13(7):e1325. doi: 10.1002/ctm2.1325

FIGURE 1.

FIGURE 1

Hepatic expression of GCN5L1 is upregulated in NASH patients and positively correlates with disease severity (A) GCN5L1 mRNA levels in liver tissues of human normal controls (n = 10), non‐alcoholic fatty liver disease (NAFLD) (n = 30), and NASH (n = 30) as determined by RT‐qPCR. (B) Western blot was used to show the expression levels of GCN5L1 protein in liver extracts from patients with normal controls, NAFLD and NASH. (C) Representative Hematoxylin and Eosin (H&E) and immunohistochemistry (IHC) images of control, NAFLD, and NASH liver sections were shown. Scale bars indicate 50 μm. (D) H&E, GCN5L1 expression by IHC, Masson staining and Sirius Red in liver sections from normal controls, NAFLD and NASH. Scale bars indicate 50 μm. (E) Representative immunofluorescence (IF) staining showed CD11b, CD68, α‐SMA and myeloperoxidase (MPO). Scale bars indicate 20 μm. (F) The correlation between GCN5L1 mRNA levels and NAS and serum alanine transaminase (ALT) levels in patients with NASH. (G) Expression profiles of GCN5L1 in mice liver. Error bars represent mean ± SD. *p < 0.05.